NASDAQ:MDGL

Madrigal Pharmaceuticals - MDGL Stock Forecast, Price & News

$240.80

+2.47 (+1.04%)

(As of 03/28/2023 12:00 AM ET)

Add

Compare

Today's Range: $238.05
▼
$245.92
50-Day Range: $231.06
▼
$307.08
52-Week Range: $57.15
▼
$315.45

Volume: 178,540 shs
Average Volume: 421,961 shs
Market Capitalization: $4.37 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $294.75

Institutional Ownership

Madrigal Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.82 Rating Score
Upside/Downside: 22.4% Upside
$294.75 Price Target
Short Interest: Bearish
8.66% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.92
Upright™ Environmental Score
News Sentiment: 1.33
Based on 4 Articles This Week
Insider Trading: Selling Shares
$10.27 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($19.59) to ($11.49) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

356th out of 1,002 stocks

Pharmaceutical Preparations Industry

160th out of 488 stocks

2.4

Analyst's Opinion

Consensus Rating
Madrigal Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $294.75, Madrigal Pharmaceuticals has a forecasted upside of 22.4% from its current price of $240.80.
Amount of Analyst Coverage
Madrigal Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
8.66% of the float of Madrigal Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Madrigal Pharmaceuticals has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Madrigal Pharmaceuticals has recently increased by 16.50%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Madrigal Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Madrigal Pharmaceuticals does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Madrigal Pharmaceuticals has received a 73.28% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Madrigal Pharmaceuticals is -0.92.

3.0

News and Social Media Coverage

News Sentiment
Madrigal Pharmaceuticals has a news sentiment score of 1.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Madrigal Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
Only 13 people have searched for MDGL on MarketBeat in the last 30 days. This is a decrease of -48% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Madrigal Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,270,610.00 in company stock.
Percentage Held by Insiders
24.49% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
67.98% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($19.59) to ($11.49) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Madrigal Pharmaceuticals is -13.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Madrigal Pharmaceuticals is -13.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Madrigal Pharmaceuticals has a P/B Ratio of 20.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MDGL Stock News Headlines

March 22, 2023 | marketbeat.com

Want Diversified Upside in Biotechnology? Check out LABU (MDGL)

Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified volatility.

March 23, 2023 | finance.yahoo.com

89bio (ETNB) Up 25% on Upbeat Data From Mid-Stage NASH Study

March 28, 2023 | The Oxford Club (Ad)

My No. 1 dividend stock for a LIFETIME of income.

Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.

March 23, 2023 | americanbankingnews.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price Down 4.3%

March 20, 2023 | americanbankingnews.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Now Covered by Analysts at StockNews.com

March 10, 2023 | finance.yahoo.com

Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle

March 10, 2023 | msn.com

Intercept to face FDA AdCom meeting on NASH candidate in May

February 26, 2023 | uk.finance.yahoo.com

MDGL Mar 2023 305.000 call

March 28, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.

January 30, 2023 | finance.yahoo.com

Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Shift From Loss To Profit

January 20, 2023 | finance.yahoo.com

Intercept's (ICPT) NDA for NASH Treatment Accepted By FDA

January 14, 2023 | seekingalpha.com

MDGL Madrigal Pharmaceuticals, Inc.

January 9, 2023 | msn.com

Here's How Much You Would Have Made Owning Madrigal Pharmaceuticals Stock In The Last 5 Years

January 7, 2023 | finance.yahoo.com

Top Picks 2023- Madrigal Pharmaceuticals MDGL

January 6, 2023 | finance.yahoo.com

Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis

January 3, 2023 | benzinga.com

This Is What Whales Are Betting On Madrigal Pharmaceuticals

January 3, 2023 | bizjournals.com

With stock up 350%, Madrigal secures more than $300M to advance NASH drug candidate

December 26, 2022 | seekingalpha.com

Madrigal Pharmaceuticals Setting The Standard

December 26, 2022 | finance.yahoo.com

This Stock That Tripled in 2022 Could Rocket Even Higher in 2023

December 23, 2022 | finance.yahoo.com

Why Madrigal Pharmaceuticals Was a Top Stock This Week

December 22, 2022 | finance.yahoo.com

Biotech Stock Roundup: MDGL Surges on NASH Data, TRDA, RCUS Down on Updates & More

December 21, 2022 | seekingalpha.com

Madrigal: Next Steps After 'Wow' Data In NASH

December 21, 2022 | seekingalpha.com

Madrigal Pharmaceuticals Is Still Undervalued After Resmetirom's Phase 3 Success

December 21, 2022 | finance.yahoo.com

Meet the Biotech Stock That Jumped Over 260% in One Day

December 20, 2022 | msn.com

Peering Into Madrigal Pharmaceuticals's Recent Short Interest

December 20, 2022 | msn.com

$1000 Invested In Madrigal Pharmaceuticals 5 Years Ago Would Be Worth This Much Today

December 20, 2022 | markets.businessinsider.com

Analyst Ratings for Madrigal Pharmaceuticals

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MDGL Company Calendar

Last Earnings: 2/23/2023
Today: 3/28/2023
Next Earnings (Estimated): 5/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:MDGL
CUSIP: 87162T20
CIK: 1157601
Web: www.madrigalpharma.com
Phone: (267) 824-2827
Fax: 781-274-8228
Employees: 71
Year Founded: 2011

Price Target and Rating

Average Stock Price Forecast: $294.75
High Stock Price Forecast: $390.00
Low Stock Price Forecast: $151.00
Forecasted Upside/Downside: +21.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.82
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($17.23)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-295,350,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -270.13%
Return on Assets: -123.03%

Debt

Debt-to-Equity Ratio: 0.25
Current Ratio: 3.12
Quick Ratio: 3.12

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $11.54 per share
Price / Book: 20.95

Miscellaneous

Outstanding Shares: 18,140,000
Free Float: 13,696,000
Market Cap: $4.39 billion
Optionable: Optionable
Beta: -0.55

Social Links

Key Executives

Paul A. Friedman
Chairman, President & Chief Executive Officer

Alex G. Howarth
Chief Financial Officer

Edward Chiang
SVP-Clinical & Technical Operations

Rebecca A. Taub
Director & Chief Medical Officer

Stephen Dodge
Senior Vice President-Global Medical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MDGL Stock - Frequently Asked Questions

Should I buy or sell Madrigal Pharmaceuticals stock right now?: 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MDGL shares.
View MDGL analyst ratings or view top-rated stocks.
What is Madrigal Pharmaceuticals' stock price forecast for 2023?: 11 brokerages have issued 1 year price targets for Madrigal Pharmaceuticals' shares. Their MDGL share price forecasts range from $151.00 to $390.00. On average, they expect the company's share price to reach $294.75 in the next twelve months. This suggests a possible upside of 22.4% from the stock's current price.
View analysts price targets for MDGL or view top-rated stocks among Wall Street analysts.
How have MDGL shares performed in 2023?: Madrigal Pharmaceuticals' stock was trading at $290.25 on January 1st, 2023. Since then, MDGL shares have decreased by 17.0% and is now trading at $240.80.
View the best growth stocks for 2023 here.
When is Madrigal Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our MDGL earnings forecast.
How were Madrigal Pharmaceuticals' earnings last quarter?: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) released its quarterly earnings results on Thursday, February, 23rd. The biopharmaceutical company reported ($4.98) EPS for the quarter, missing the consensus estimate of ($4.61) by $0.37.
What ETFs hold Madrigal Pharmaceuticals' stock?: ETFs with the largest weight of Madrigal Pharmaceuticals (NASDAQ:MDGL) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco DWA Healthcare Momentum ETF (PTH), Invesco Nasdaq Future Gen 200 ETF (QQQS), iShares U.S. Pharmaceuticals ETF (IHE), Alger Mid Cap 40 ETF (FRTY), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).

What other stocks do shareholders of Madrigal Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Ayala Pharmaceuticals (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild).
What is Madrigal Pharmaceuticals' stock symbol?: Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."
Who are Madrigal Pharmaceuticals' major shareholders?: Madrigal Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Avoro Capital Advisors LLC (9.71%), Avidity Partners Management LP (2.51%), Susquehanna International Group LLP (0.00%), Geode Capital Management LLC (1.38%), Artisan Partners Limited Partnership (1.24%) and Armistice Capital LLC (1.22%). Insiders that own company stock include Bay City Capital Llc, Brian Joseph Lynch, Fred B Craves, Remy Sukhija and Richard S Levy.
View institutional ownership trends.
How do I buy shares of Madrigal Pharmaceuticals?: Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Madrigal Pharmaceuticals' stock price today?: One share of MDGL stock can currently be purchased for approximately $240.80.
How much money does Madrigal Pharmaceuticals make?: Madrigal Pharmaceuticals (NASDAQ:MDGL) has a market capitalization of $4.37 billion. The biopharmaceutical company earns $-295,350,000.00 in net income (profit) each year or ($17.23) on an earnings per share basis.
How can I contact Madrigal Pharmaceuticals?: Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The official website for the company is www.madrigalpharma.com. The biopharmaceutical company can be reached via phone at (267) 824-2827, via email at ir@madrigalpharma.com, or via fax at 781-274-8228.

This page (NASDAQ:MDGL) was last updated on 3/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Madrigal Pharmaceuticals - MDGL Stock Forecast, Price & News

Madrigal Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

MDGL Stock News Headlines

MDGL Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

MDGL Stock - Frequently Asked Questions

Overall MarketRank^™